Shares of HQY.O reached a 20-day high today, reflecting a positive momentum in the stock despite broader market challenges. This technical breakout signals a potential shift in investor sentiment, as the stock has shown resilience amid recent volatility.
The recent quarterly performance of LifeMD, Inc. revealed a loss of $0.1 per share, which fell short of the Zacks Consensus Estimate of a loss of $0.06. Revenue for the quarter was reported at $60.17 million, slightly below expectations but an increase from $53.39 million year-over-year.
Despite these mixed results, LifeMD's stock has underperformed the S&P 500 this year, declining by 6.5%. The Medical Services industry, where LifeMD operates, is currently ranked in the bottom 43% of Zacks industries, indicating that external factors may continue to influence the stock's trajectory.
Wall Street analysts forecast HQY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HQY is 117.09 USD with a low forecast of 89.00 USD and a high forecast of 129.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast HQY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HQY is 117.09 USD with a low forecast of 89.00 USD and a high forecast of 129.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 83.570
Low
89.00
Averages
117.09
High
129.00
Current: 83.570
Low
89.00
Averages
117.09
High
129.00
Goldman Sachs
Neutral -> Sell
downgrade
$89
2026-01-09
Reason
Goldman Sachs
Price Target
$89
AI Analysis
2026-01-09
downgrade
Neutral -> Sell
Reason
Goldman Sachs downgraded HealthEquity to Sell from Neutral with an $89 price target. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note. The firm thinks the stock's multiple will come under pressure until the next leg of growth opportunity emerges.
KeyBanc
Scott Schoenhaus
Overweight
maintain
$120 -> $125
2026-01-08
Reason
KeyBanc
Scott Schoenhaus
Price Target
$120 -> $125
2026-01-08
maintain
Overweight
Reason
KeyBanc analyst Scott Schoenhaus raised the firm's price target on HealthEquity to $125 from $120 and keeps an Overweight rating on the shares. Coming off a choppy year for HCIT stocks, fundamentally, the firm did see a "year of inflection" for many of its names with estimate revisions plus valuations largely bottoming. While KeyBanc expects momentum to continue for most of its coverage, the firm does see valuation multiples impacted by competition concerns and regulatory impacts.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HQY
Unlock Now
Barclays
Peter Warendorf
Overweight
initiated
$118
2025-12-08
Reason
Barclays
Peter Warendorf
Price Target
$118
2025-12-08
initiated
Overweight
Reason
Barclays analyst Peter Warendorf initiated coverage of HealthEquity with an Overweight rating and $118 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Deutsche Bank
Buy
maintain
$117 -> $120
2025-12-05
Reason
Deutsche Bank
Price Target
$117 -> $120
2025-12-05
maintain
Buy
Reason
Deutsche Bank raised the firm's price target on HealthEquity to $120 from $117 and keeps a Buy rating on the shares following the Q3 report. The firm sees "multiple growth options" for the company.
About HQY
HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
